Human protein phosphatase 2C

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time for Utility, Provisional or Design Patent Creation with PowerPatent software and services.

The Incyte Corporation patent solves the following problem:

Change protein phosphorylation is ubiquitous methods used to control many of intracellular events in eukaryotic cells. It is estimated that more than ten percent of the active protein in a typical mammal cell are phosphorylated. Kinases to facilitate the transfer of high-energy phosphate group from adenosine triphosphate (ATP) to the target protein hydroxyamino acid residues serine, threonine, or tyrosine. Phosphatases, in contrast, take the phosphate groups. Extracellular signal including the hormone, neurotransmitter, growth and inequality factors may activate kinases, which takes place as the cell surface of cells or as activator in the final effector proteins, as well as other places along the way signal transduction. Cascade of kinases occur, as well as sensitive kinases second messenger molecules. This system allows for equipment to amplify the weak signal (lower abundance of growth factor molecules, for example), as well as the synthesis of many weak signal into an all-or-nothing answer. Phosphatases, then, is necessary to determine the extent of phosphorylation in cells and, with kinases, controlling key cellular processes such as metabolic enzyme activity, proliferation, cell growth and inequality, cell adhesion, and cell cycle progression.

Our analysis of this patent is as follows:

Incyte Corporation’s patent US 7029897 B2 deals with Human protein phosphatase 2C.
invention provides human kinases and phosphatases (KAP) and polnucleotides to recognize and encode KAP. invention also provides expresson vector, host cells, antibodies, agonists and antagonists. invention also provides methods for diagnosing, treating, or preventing diseases associated with aberrant expression of KAP.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Isolated polynucleotide encoding a human PSST subunit of the NADH:ubiquinone oxidoreductase complex

Use PowerPatent’s Online Patent Filing Service to get quick patent protection for your great idea.

The Incyte Corporation patent solves the following problem:

Mitochondria are the main areas of energy production in cells. Energy of the oxidation of glucose and fatty acids. Glucose is first oxidized to pyruvate in the cytoplasm. Fatty acid and pyruvate brought into the mitochondria for complete oxidation to CO2 coenzyme A (COA). It oxidation with enzymes that transport electrons from NADH and FADH2 to oxygen and synthesis of ATP (oxidative phosphorylation) from ADP and Pi. ATP synthesis is carried out in F0F1 ATPase complex in the mitochondrial inner membrane. ATP then provides the main source of energy for driving many energy-requiring reactions in a cell.

Our analysis of this patent is as follows:

Incyte Corporation’s patent US 7022507 B1 deals with Isolated polynucleotide encoding a human PSST subunit of the NADH:ubiquinone oxidoreductase complex.
invention provides human mitochondrial protein (MITP) and polynucleotides which identify and encode MITP. invention also provides expression vector, host cells, antibodies, agonists and antagonists. invention also provides methods for diagnosing, treating, or preventing diseases associated with expression of MITP.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.